Neurocrine presents data from Ingrezza studies on tardive dyskines patients

Neurocrine (NBIX) Biosciences presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA, or valbenazine, capsules. These data showed significant improvements in functional, social, emotional and health-related quality of life measures in Phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients’ lives and antipsychotic adherence in real-world practice. This research was shared at the 2024 Psych Congress in Boston. This analysis was conducted using combined data from 252 patients who completed the Phase 3 KINECT-3 or KINECT-4 studies. The 11-item Tardive Dyskinesia Impact Scale, or TDIS, a validated patient-reported outcome measure, was used to evaluate tardive dyskinesia, or TD, symptom impact at baseline through Week 48. TDIS scores range from 0 to 4 for each item, with higher scores indicating greater impact and decreases in scores indicating improvement. Results showed consistent improvements across all items, suggesting treatment with INGREZZA improved TDIS scores for both physical and socio-emotional domains. The most impacted items at baseline were self-consciousness, embarrassment, mouth noises, unwanted attention and writing. Improvements of 1 point or more from baseline to Week 48 were observed in self-consciousness, embarrassmen and mouth noises. Unwanted attention and writing also improved considerably.